

Female Urology, Urodynamics, Incontinence, and Pelvic Floor Reconstructive Surgery

Assessment of Renal Deterioration and Associated Risk Factors in Patients With Multiple Sclerosis



Nabeel A. Shakir, Arthi Satyanarayan, Jessica Eastman, Benjamin M. Greenberg, and Gary E. Lemack

OBJECTIVE	To evaluate predictors of renal deterioration (RD) in patients with multiple sclerosis (MS) at a tertiary referral center.
METHODS	We reviewed adult patients with MS presenting for evaluation of lower urinary tract symptoms, with baseline urodynamic study (UDS) and either serum creatinine (SCr) or renal ultrasound, from a prospectively maintained database, and excluded patients with abnormal renal function. RD was defined as doubled SCr, new hydronephrosis, or renal atrophy on follow-up ultrasound. Demographic and UDS parameters were evaluated in multivariable models of RD.
RESULTS	From 1999 to 2016, 660 patients were evaluated, and 355 met criteria with median follow-up of 79 months. SCr doubled in 8 patients, 4 had decline by renal ultrasound, and 1 by both (3%). Overall, 46 patients met less strict criteria of decrease in estimated glomerular filtration rate by $\geq 30\%$. Using the less rigid criterion, detrusor overactivity (DO) remained associated with RD on multivariable analysis. Eleven of 355 patients had RD by either imaging or doubled Cr, with which only history of diabetes mellitus and nephrolithiasis were associated.
CONCLUSION	By strict criteria, the rate of RD in patients with neurogenic bladder due to MS was low (3%) at intermediate-term follow-up and was not associated with UDS parameters. Using more liberal criteria, DO was associated with deterioration, suggesting that study of the impact of more aggressive control of DO in this population may be warranted. UROLOGY 123: 76–80, 2019. © 2018 Elsevier Inc.

Patients suffering from neurogenic bladder (NGB) related to multiple sclerosis (MS) often report lower urinary tract symptoms (LUTS) have urodynamic (UD) abnormalities on functional testing, and may develop renal deterioration (RD).¹ Of all patients with MS, 65%-75% report moderate to severe LUTS, and symptom prevalence increases progressively with disease duration.² Concomitantly, UD findings in symptomatic patients include detrusor overactivity (DO) most commonly (mean 70%), followed by detrusor-external sphincter dyssynergia (DESD, 28%) and detrusor underactivity (15%).³ Despite the high proportion of LUTS and UD

abnormalities, the incidence of RD secondary to NGB in patients with MS appears to be low overall.⁴

Although studies to date have identified duration of disease and Expanded Disability Status Scale (EDSS) score as potential predictors of RD,⁵ and EDSS in particular as a predictor of UD abnormalities,⁶ whether the association established in other populations (ie, abnormal compliance in patients with myelomeningocele) also holds true for those with MS is uncertain.^{7,8} In this study, we evaluated the risk and potential predictors of RD, assessed clinically and radiographically, in a population of patients with NGB secondary to MS followed over time at a tertiary referral center.

Conflicts of Interest: The authors declare that there is no conflict of interest.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

From the Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; and the Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX

Address correspondence to: Gary E. Lemack, M.D., Department of Urology, University of Texas Southwestern Medical Center, Room JA5.130D, 5323 Harry Hines Blvd., Dallas, TX 75390-9110. E-mail: Gary.Lemack@UTSouthwestern.edu

Submitted: July 16, 2018, accepted (with revisions): September 18, 2018

MATERIALS AND METHODS

Patient Selection

Following Institutional Review Board approval, we reviewed a prospectively maintained database of consecutive adult patients with MS referred for evaluation of LUTS to our center from December 1999 to September 2016. Patients underwent detailed history and physical examination, baseline measurement of

serum creatinine (SCr), and most underwent a recommended baseline, UDs, renal ultrasound (RUS), as well as repeat studies as clinically appropriate. We included subjects who had at least 2 office visits and serial determination of SCr, RUS, or both with follow-up ≥ 6 months. Patients with elevated SCr at the initial visit, prior nephrectomy, or other neurologic diagnosis were excluded. Demographic and clinical data including type of MS (primary progressive, relapsing-remitting, and secondary progressive), time since diagnosis, and bladder management at presentation (voiding spontaneously, clean intermittent catheterization, or indwelling catheter) were recorded. As EDSS was unavailable for a majority of patients, we determined physical mobility status in terms of wheelchair use, as patients with lower extremity motor loss are more likely to have lower urinary tract dysfunction.⁹

Urodynamic Assessment

For patients who underwent UD testing, the study was performed and interpreted by one investigator (G.E.L.) under guidelines established by the International Continence Society.¹⁰ All patients who had urodynamic study (UDS) were without urinary tract infection at the time of the procedure. Our multichannel videourodynamics protocol utilized a dual lumen 6 French vesical and 10 French rectal catheter with fill rates of 25-50 mL/min and external urethral sphincter activity measured with surface electromyographic electrodes (Laborie Medical Technologies Inc., Toronto, Canada). Maximum cystometric capacity (MCC), DESD by surface electromyographic and fluoroscopic evidence during voiding, maximum flow rate (Q_{max}) and detrusor pressure at Q_{max} , and postvoid residual were recorded. DO was defined as involuntary rise in detrusor pressure of ≥ 5 cm H₂O during filling, and decreased compliance was defined as vesical pressure ≤ 10 mL/cm H₂O from initial measurement to MCC.

Outcomes

RUS abnormalities were defined as new onset hydronephrosis or cortical atrophy on repeat RUS if a baseline study was performed. All ultrasound studies were performed as part of clinical care and interpreted at our institution by radiologists uninvolved in the study protocol. Estimated glomerular filtration rate (eGFR) was calculated for all patients with measured SCr using the Cockcroft-Gault formula and the body weight corresponding to the date of SCr. RD was defined as either doubling of SCr, or development of new abnormalities on most recent RUS. A more liberal criterion of $\geq 30\%$ decline in eGFR was also used based on its potential prognostic significance for the development of end-stage renal disease, relative to the traditional cutoff of doubled SCr.¹¹ Interventions during the study period, including starting anticholinergics or alpha-blockers de novo, change in bladder management, or undergoing intravesical botulinum toxin injection, were recorded for each patient. For patients who underwent urinary diversion, the SCr and RUS just prior to surgery were utilized.

Statistical Analysis

The R software package was used for all analyses. Continuous variables were compared with the Mann-Whitney U test and categorical variables with Fisher's exact test. To determine whether UD parameters were associated with the development of RD, they were evaluated via univariate and multivariable logistic regression together with potential demographic and

clinical covariates among patients with initial UDS. Parameters meeting a threshold $P < .15$ were included in a final multivariable model where significance was defined as $P < .05$.

RESULTS

Demographics

Of 660 patients who were evaluated during the study period, 355 met criteria with median overall follow-up of 79 months (interquartile range: 49-122). One patient who had previous nephrectomy, 2 whose neurologic diagnosis was reclassified as acute demyelinating encephalomyelitis, 120 who did not undergo baseline UDS, and 183 who did not have follow-up imaging or SCr were excluded. Demographic and clinical data are summarized in Table 1. History of nephrolithiasis was noted in 10% of

Table 1. Demographic data for the 355 patients in the study

Parameter	
Age at presentation	51 (43-58)
Body-mass index, kg/m ²	25 (22-30)
Gender, no. (%)	
Female	271 (76%)
Male	84 (24%)
Race, no. (%)	
Black	17 (5%)
Hispanic	10 (3%)
Other or unknown	48 (14%)
White	280 (79%)
Taking anticholinergics at baseline, no. (%)	148 (42%)
Wheelchair bound, no. (%)	42 (12%)
Time since diagnosis of multiple sclerosis, years	11 (5-18)
Type of multiple sclerosis, no. (%)	
Primary progressive	36 (10%)
Relapsing-remitting	191 (54%)
Secondary progressive	123 (35%)
Unknown	5 (1%)
History of nephrolithiasis, no. (%)	35 (10%)
Hypertension, no. (%)	102 (29%)
Type 2 diabetes, no. (%)	19 (5%)
SCr at baseline, mg/DL	0.8 (0.7-0.9)
eGFR at baseline, mL/min	102 (84-127)
Renal ultrasound at baseline, no. (%)	
Cortical atrophy, unilateral	4 (1%)
Hydronephrosis, unilateral	10 (3%)
Normal	209 (59%)
Unavailable	132 (37%)
Follow-up, months	79 (49-122)
Renal deterioration, no. (%)	
By change in imaging	5 (1%)
By decline in eGFR by $\geq 30\%$	42 (12%)
By doubled SCr	7 (2%)
By either imaging or doubled SCr	11 (3%)
By either imaging or eGFR	46 (13%)
Started following UDS, no. (%)	
Alpha blockers	9 (3%)
Anticholinergics	11 (3%)
Change in bladder management	90 (25%)
Intravesical Botox	34 (10%)

eGFR, estimated glomerular filtration rate; SCr, serum creatinine; UDS, urodynamic study. Continuous variables are reported as medians with interquartile ranges (IQR) in parentheses.

patients. Of 223 of 355 patients who had baseline RUS, abnormalities were present in 14 of 223 (6%) and were principally unilateral hydronephrosis.

Rate of Renal Deterioration

Serial SCr measurements were available for 340 of 355 patients and follow-up RUS for 146 of 355. For the 146 patients with serial imaging, the median interval follow-up between the initial and most recent imaging study was 94 months (interquartile range: 54-140). The overall rate of RD by strict criteria (doubled SCr or new RUS abnormality) was 11 of 355 (3%), and by liberal criteria 46 of 355 (13%, Table 1). RD was driven primarily by decline in eGFR; only 5 patients had new RUS abnormalities. There was no association between change in imaging findings and decline in eGFR ($P = .5$). Most patients (235/355) had follow-up >60 months and the majority of RD occurred at or beyond this time point (Fig. 1). Supplementary Figure 1 summarizes follow-up and outcomes for the study population.

Urodynamic Assessment and Bladder Management

DO was noted on UDS in 153 of 355 patients, DESD in 107 of 355, and decreased compliance in 25 of 355 (Table 2). The only UD parameter associated with development of RD by liberal criteria was DO ($P = .01$). Patients with both DO and DESD (62/355) were not more likely to have RD (12/62 vs 34/293, $P = .1$). Patients with RD had similar MCC, Q_{max} , and postvoid residual as those without RD. Most patients (293/355) were voiding at initial visit, and of these 293, 233 were voiding at most recent follow-up. Clean intermittent catheterization was ultimately employed by 72 of 355, indwelling catheter by 45 of 355, and 5 of 355 underwent urinary diversion during the study period (2 for bladder cancer). There was no association between change in bladder management and development of RD ($P = .7$).

Multivariable Analysis

Demographic and clinical parameters meeting a threshold $P < .15$ on univariate logistic regression models of RD by liberal criteria (Table 3) were body-mass index ($P = .04$), history of nephrolithiasis ($P = .02$), hypertension ($P = .1$), type 2 diabetes mellitus ($P = .08$), presence of DO ($P = .01$), and detrusor pressure at Q_{max} ($P = .1$). In the final multivariable model, presence of DO remained associated with development of RD (using liberal criteria) when controlling for potentially confounding parameters, with odds ratio (OR) 3.80 (95% confidence interval [CI] 1.34-10.8, $P = .006$). Of note, change in bladder management, de novo use of anticholinergic or alpha-blocker medication, or intravesical botulinum toxin injection following UDS were not associated with RD.

Due to the small number of patients with RD by strict criteria (11/355), multivariable analysis was not performed for this outcome to avoid possible overfitting. However, the only variables significantly associated with RD by strict criteria in patients who had initial UDS were history of diabetes (OR 7.69, 95% CI 1.86-31.8, $P = .02$) and history of nephrolithiasis (OR 8.72, 95% CI 2.51-30.3, $P = .002$).

DISCUSSION

While early studies indicated rates of upper urinary tract dysfunction as high as 25% in patients with MS, more current epidemiologic data suggest that the risk for RD may have been significantly overestimated.^{12,13} Improved and earlier diagnosis of MS, availability of disease-modifying therapies, and advances in the identification and treatment of LUTS may have contributed to this decrease. Since UDs are commonly employed to assess LUTS in patients with MS, identification of UDS parameters associated with RD would be of significant value.¹⁴ Our group and others previously estimated the rate of abnormalities




Figure 1. Renal deterioration by time of follow-up for all patients in the study. eGFR, estimated glomerular filtration rate. SCr, serum creatinine. (Color version available online.)

Table 2. Urodynamic parameters of patients in the study

Parameter	Renal Deterioration		P
	No (n = 309)	Yes (n = 46)	
Decreased bladder compliance	21 (7%)	4 (9%)	.5
DESD, no. (%)	94 (30%)	13 (28%)	.9
Detrusor overactivity, no. (%)	125 (40%)	28 (61%)	.01
Amplitude of DO, cm H ₂ O	29 (10-50)	28 (20-51)	.7
End-fill bladder pressure, cm H ₂ O	42 (31-57)	36 (28-43)	.3
Maximum cystometric capacity, mL	331 (185-500)	265 (152-469)	.2
Detrusor leak point pressure, cm H ₂ O*	36 (26-64)	43 (35-50)	.9
Voiding spontaneously, no. (%)	84 (27%)	13 (28%)	.9
Maximum flow, mL/s	8 (4-14)	8 (5-11)	.5
Detrusor pressure at maximal flow, cm H ₂ O	34 (20-48)	25 (18-37)	.1
Postvoid residual	95 (7-247)	32 (0-144)	.2

DESD, detrusor-external sphincter dyssynergia; DO, detrusor overactivity.

Renal deterioration is defined here as either at least 30% decline in eGFR, or change in follow-up imaging. Continuous variables are reported as medians with interquartile ranges (IQR) in parentheses.

* Measurable in 7 patients.

on initial and short-term follow-up RUS in patients with MS as 4%-5%.^{4,15,16} The present report builds on these data, incorporating imaging and renal functional outcomes and demonstrating that the overall development of RD at intermediate-term follow-up is low – 3% by strict criteria – regardless of UD or demographic predictors.

Since it is clear that RD can and does occur late (> 60 months) in other neurogenic bladder conditions, continued surveillance in this population is appropriate. Although MS burden was not specifically quantified in this study, proxy variables such as the proportions of patients who were on anticholinergic therapy or

wheelchair bound at initial visit were instead evaluated. Furthermore, potentially confounding covariates, including interventions following UDS (starting anticholinergic or alpha-blocker medications de novo, changing bladder management or undergoing intravesical botulinum toxin injection), were found not to be significantly associated with RD on univariate analysis or were controlled for in multivariable analysis. Nevertheless, other parameters could have contributed to the outcome. For example, while not available for review in this population, EDSS scoring may be useful in renal risk stratification, and merits further study.⁵

Table 3. Univariate and multivariable analysis of predictors of renal deterioration by liberal criteria (≥ 30% decline in eGFR or change in imaging) in patients with UDS

Parameter	Univariate		Multivariable	
	OR	P	OR	P
Age, per year	0.99 (0.97-1.03)	.9	-	-
Body-mass index, per kg/m ²	1.05 (1.00-1.09)	.04	1.06 (1.00-1.13)	.06
Gender, female vs male	1.32 (0.61-2.86)	.5	-	-
Taking anticholinergics at baseline, yes/no	1.20 (0.65-2.24)	.6	-	-
Time since diagnosis of MS, per year	0.99 (0.96-1.03)	.7	-	-
Type of MS, RRMS vs others	1.26 (0.67-2.35)	.5	-	-
Wheelchair bound, yes/no	1.14 (0.45-2.87)	.8	-	-
History of nephrolithiasis, yes/no	2.65 (1.15-6.08)	.02	1.86 (0.57-6.04)	.3
Hypertension, yes/no	1.72 (0.91-3.28)	.1	2.29 (0.94-5.62)	.07
Type 2 diabetes, yes/no	2.57 (0.88-7.51)	.08	1.43 (0.29-7.07)	.7
Decreased bladder compliance, yes/no	1.31 (0.43-3.99)	.6	-	-
DESD, no. (%)	0.89 (0.45-1.76)	.7	-	-
DO, yes/no	2.29 (1.21-4.32)	.01	3.80 (1.34-10.8)	.006
Amplitude of DO, per cm H ₂ O	1.00 (0.99-1.02)	.7	-	-
Endfill bladder pressure, per cm H ₂ O	0.96 (0.88-1.05)	.3	-	-
Maximum cystometric capacity, per mL	0.99 (0.99-1.00)	.2	-	-
Detrusor leak point pressure, per cm H ₂ O	0.99 (0.92-1.08)	.9	-	-
Voiding spontaneously, yes/no	1.06 (0.53-2.10)	.9	-	-
Maximum flow, per mL/s	0.99 (0.94-1.03)	.5	-	-
Detrusor pressure at maximum flow, per cm H ₂ O	0.98 (0.97-1.00)	.1	0.98 (0.95-1.00)	.06
Postvoid residual, per mL	0.99 (0.99-1.00)	.2	-	-
Change in bladder management after UDS, yes/no	0.86 (0.42-1.64)	.8	-	-
Received intravesical Botox after UDS, yes/no	1.12 (0.43-3.21)	.7	-	-
Started alpha blocker after UDS, yes/no	1.96 (0.39-9.74)	.4	-	-
Started anticholinergics after UDS, yes/no	2.63 (0.67-10.3)	.2	-	-

MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.

For patients undergoing UDS, the only factor remaining significantly associated with RD by liberal criteria on multivariable regression was the presence of DO. Previous studies have yielded conflicting results regarding the possible prognostic value of decreased compliance, DESD, male gender, or change in bladder management;^{15,17,18} however, none of these parameters were predictive of RD in the current analysis. The relative infrequency of poor compliance, and the recognition that DESD does not result in greatly elevated intravesical pressures in MS patients may partially explain the failure to find an association with these UD variables and RD.^{8,19} Further, DO due to MS has been associated with greater amplitude and increased threshold volume for detrusor contraction than idiopathic DO, again suggesting upper tracts may be at greater risk than most patients with OAB (overactive bladder).²⁰ The impact of early treatment of DO and close monitoring of renal function for patients found to have DO on initial testing should be studied on the basis of our findings.

Despite the low risk of RD in the patient cohorts, the retrospective nature of this study limits direct comparison, in addition to resulting in incomplete data for follow-up imaging. We excluded patients with multiple neurologic diagnoses or prior nephrectomy, and additional scrutiny in such populations may be indicated. Patients with abnormal compliance or DESD, or male patients, may be considered for closer follow-up with RUS and UDS due to conflicting literature regarding increased risk of RD, though the current study did not indicate an enhanced risk.²¹ Lastly, data regarding other risk factors for RD, including recurrent urinary tract infections, were not available for review due to the referral nature of our patient population.

CONCLUSION

The rate of RD in patients referred with NGB due to MS was low (3%) at median follow-up of 79 months. Using more liberal criteria, DO was associated with renal deterioration, suggesting that study of the impact of more aggressive control of DO in this population may be warranted.

SUPPLEMENTARY MATERIALS

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.urology.2018.09.014](https://doi.org/10.1016/j.urology.2018.09.014).

References

1. Phe V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. *Nat Rev Urol*. 2016;13:275–288.

2. Stoffel JT. Chronic urinary retention in multiple sclerosis patients: physiology, systematic review of urodynamic data, and recommendations for care. *Urol Clin North Am*. 2017;44:429–439.
3. Harris CJ, Lemack GE. Neurourologic dysfunction: evaluation, surveillance, and therapy. *Curr Opin Urol*. 2016;26:290–294.
4. Fletcher SG, Dillon BE, Gilchrist AS, et al. Renal deterioration in multiple sclerosis patients with neurovesical dysfunction. *Mult Scler*. 2013;19:1169–1174.
5. Neichen BV, Schneider MP, Hlavica M, Hagenbuch N, Linnebank M, Kessler TM. High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis. *Mult Scler* 2017; 1352458517703801.
6. Castel-Lacanal E, Game X, Clanet M, et al. Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patients. *NeuroUrol Urodyn*. 2015;34:32–36.
7. Nseyo U, Santiago-Lastra Y. Long-term complications of the neurogenic bladder. *Urol Clin North Am*. 2017;44:355–366.
8. Lemack GE, Frohman E, Ramnarayan P. Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures. *Urology*. 2007;69:893–897.
9. De Ridder D, Van Der Aa F, Debruyne J, et al. Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis. *Clin Neurol Neurosurg*. 2013;115:2033–2040.
10. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. *NeuroUrol Urodyn*. 2002;21:167–178.
11. Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. *JAMA*. 2014;311:2518–2531.
12. Jameson RM. Management of the bladder in non-traumatic paraplegia. *Paraplegia*. 1974;12:92–97.
13. Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. Renal failure in patients with neurogenic lower urinary tract dysfunction. *Neuroepidemiology*. 2001;20:138–143.
14. Winters JC, Dmochowski RR, Goldman HB, et al. Urodynamic studies in adults: AUA/SUFU guideline. *J Urol*. 2012;188:2464–2472.
15. Krhut J, Hradilek P, Zapletalova O. Analysis of the upper urinary tract function in multiple sclerosis patients. *Acta Neurol Scand*. 2008;118:115–119.
16. Onal B, Siva A, Buldu I, Demirkesen O, Cetinel B. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis. *Int Braz J Urol*. 2009;35:326–333.
17. Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 1993;56:245–250.
18. Blaivas JG, Barbalias GA. Detrusor-external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. *J Urol*. 1984;131:91–94.
19. Sirls LT, Zimmern PE, Leach GE. Role of limited evaluation and aggressive medical management in multiple sclerosis: a review of 113 patients. *J Urol*. 1994;151:946–950.
20. Lemack GE, Frohman EM, Zimmern PE, Hawker K, Ramnarayan P. Urodynamic distinctions between idiopathic detrusor overactivity and detrusor overactivity secondary to multiple sclerosis. *Urology*. 2006;67:960–964.
21. Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology (EAU) guidelines on neuro-urology. *Eur Urol*. 2016;69:324–333.